---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Clinical trials questions"
description: "Clinical trials questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Long-term results. Questions: How were the Kesimpta ASCLEPIOS I and II trials designed? Kesimpta vs Aubagio (teriflunomide): how much lower was the relapse rate? Does Kesimpta slow disability progression compared with Aubagio (teriflunomide)? How much does Kesimpta reduce MS lesions on MRI compared with Aubagio? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Clinical trials questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Clinical trials

<a id="kesimpta-asclepios-design"></a>

### How were the Kesimpta ASCLEPIOS I and II trials designed?

> “ASCLEPIOS I and II were 2 identical, randomized, active-controlled, double-blind Phase 3 studies in patients with relapsing MS, approximately 40% of whom were DMT treatment naïve. Patients were randomized to double-dummy SC KESIMPTA (20 mg every 4 weeks) or oral Aubagio<sup>®</sup> (teriflunomide) (14 mg daily) for up to 30 months. Primary end point was ARR. Key secondary end points were number of Gd+ T1 lesions and annualized rate of NE T2 lesions, and reduction in risk of 3-month CDP. Treatment duration was variable based on end-of-study criteria. Maximum duration: 120 weeks; median duration: 85 weeks.<sup>1</sup>”

Source: [KESIMPTA: Clinical Study Design, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/study-design#:~:text=ASCLEPIOS%20I%20and%20II%20were,120%20weeks%3B%20median%20duration%3A%2085)

> “Both studies enrolled patients with at least one relapse in the previous year, 2 relapses in the previous 2 
> years, or the presence of a T1 gadolinium-enhancing (GdE) lesion in the previous year. Patients were also required to have 
> an Expanded Disability Status Scale (EDSS) score from 0 to 5.5.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

<a id="kesimpta-vs-aubagio-relapse-rate"></a>

### Kesimpta vs Aubagio (teriflunomide): how much lower was the relapse rate?

> “The primary endpoint of both trials was the annualized relapse rate (ARR) over the treatment period.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

> “In both studies, KESIMPTA significantly lowered the ARR compared to teriflunomide.”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “Table 2: Key Clinical and MRI Endpoints From Study 1 and Study 2  
> Endpoints 
> Study 1  
> Study 2  
> KESIMPTA 
> 20 mg 
> (n = 465) 
> Teriflunomide 
> 14 mg 
> (n = 462) 
> KESIMPTA 
> 20 mg  
> (n = 481) 
> Teriflunomide 
> 14 mg 
> (n = 474)”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “Annualized relapse rate (primary 
> endpoint) 
> 0.11 
> 0.22 
> 0.10 
> 0.25 
> Relative reduction 
> 51% (p < 0.001) 
> 58% (p < 0.001)”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2.

<a id="kesimpta-vs-aubagio-disability"></a>

### Does Kesimpta slow disability progression compared with Aubagio (teriflunomide)?

> “KESIMPTA significantly reduced the risk of 3-month confirmed disability progression compared to teriflunomide.”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “Proportion of patients with 3-month 
> confirmed disability progression<sup>a,b</sup> 
> 10.9% KESIMPTA vs 15.0% teriflunomide 
>
>
> Relative risk reduction 
> 34.3% (p = 0.003)”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “<sup>a</sup>Disability progression was defined as an increase in EDSS of at least 1.5, 1, or 0.5 points in patients with a baseline EDSS of 0, 1 to 5, or 5.5 or 
> greater, respectively. 
> <sup>b</sup>Prospective pooled analysis of Studies 1 and 2. Proportion of patients with 3-month confirmed disability progression refers to Kaplan-Meier 
> estimates at Month 24.”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2. The kesimptahcp.com clinical trial results page gives 0.65 points for a baseline EDSS of 5.5 or greater in a footnote to a post hoc subgroup analysis; the Prescribing Information, the FAQ page, and the Authorization and Appeals Kit give 0.5 points.

<a id="kesimpta-vs-aubagio-mri-lesions"></a>

### How much does Kesimpta reduce MS lesions on MRI compared with Aubagio?

> “KESIMPTA significantly reduced the number of T1 GdE lesions and the rate of new or enlarging T2 lesions in both 
> studies.”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “Table 2: Key Clinical and MRI Endpoints From Study 1 and Study 2  
> Endpoints 
> Study 1  
> Study 2  
> KESIMPTA 
> 20 mg 
> (n = 465) 
> Teriflunomide 
> 14 mg 
> (n = 462) 
> KESIMPTA 
> 20 mg  
> (n = 481) 
> Teriflunomide 
> 14 mg 
> (n = 474)”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “MRI Endpoints 
> Mean number of T1 Gd-enhancing 
> lesions per MRI scan 
> 0.01 
> 0.46 
> 0.03 
> 0.52 
> Relative reduction 
> 98% (p < 0.001) 
> 94% (p < 0.001) 
> Number of new or enlarging T2 lesions 
> per year 
> 0.72 
> 4.00 
> 0.64 
> 4.16 
> Relative reduction 
> 82% (p < 0.001) 
> 85% (p < 0.001)”

Source: [KESIMPTA: Prescribing information, page 11, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=11)

> “Additional outcome 
> measures included: 1) the time to 3-month confirmed disability progression for the pooled populations, 2) the number of 
> T1 GdE lesions per scan at Weeks 48 and 96, and 3) the annualized rate of new or enlarging T2 MRI lesions.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

Note: The Prescribing Information calls the two identical phase 3 trials, ASCLEPIOS I and ASCLEPIOS II, Study 1 and Study 2.

## Long-term results

<a id="kesimpta-alithios-neda-7-years"></a>

### How many Kesimpta patients had no evidence of disease activity in year 7 (ALITHIOS)?

> “No evidence of disease activity (NEDA-3) for 95% of patients at year 7<sup>6,18</sup>”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=No%20evidence%20of%20disease%20activity%20%28NEDA%2D3%29%20for%2095%25%20of%20patients%20at%20year)

> “NEDA-3 post hoc analysis limitations: This analysis considers patients without evidence of disease activity (which may also include patients with partially missing information) as NEDA-3. A sensitivity analysis was conducted for the population of patients who completed the full 24 months of treatment.<sup>19</sup> No conclusions of clinical outcomes can be drawn.”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=NEDA%2D3%20post%20hoc%20analysis%20limitations%3A,clinical%20outcomes%20can%20be%20drawn.)

> “NEDA-3 post hoc analysis design: All patients from the pivotal trials, full analysis set population (all randomized patients with assigned treatments) who also received KESIMPTA in the ALITHIOS extension study (data cutoff: September 25, 2024) were included in the intent-to-treat principle except for patients who had reached NEDA-3 but discontinued from the study drug prematurely for reasons other than “lack of efficacy” or “death.” The outcomes presented here are the proportion of study patients within a treatment group who met the NEDA-3 criteria vs those who did not. The proportion of patients meeting NEDA-3 criteria was analyzed cross sectionally in 1-year time intervals across 7 years. Within the prespecified time period, patients who achieved NEDA-3 experienced no 6-month CDP; no confirmed relapse; no Gd+ T1 lesions; no NE T2 lesions; and no discontinuation from the study drug due to either lack of efficacy or death.<sup>4,19</sup>”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=NEDA%2D3%20post%20hoc%20analysis%20design%3A,either%20lack%20of%20efficacy%20or)

> “ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.<sup>4-9</sup>”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=conclusions%20can%20be%20drawn.-,ALITHIOS%20study%20design%3A%20ALITHIOS%20is%20an%20open%2Dlabel%2C%20umbrella%20extension%2C%20Phase,treatment%2Dna%C3%AFve%20subgroup%20treated%20with%20KESIMPTA.4%2D9)

<a id="kesimpta-alithios-disability-7-years"></a>

### What were Kesimpta disability progression rates at 7 years (ALITHIOS extension)?

> “In the extension study, at 7 years
>
> Cumulative 3-month disability progression: KESIMPTA initiators, 26.3%; Aubagio to KESIMPTA switch, 29.8%<sup>15</sup>
>
> Cumulative 6-month disability progression: KESIMPTA initiators, 22.7%; Aubagio to KESIMPTA switch, 26.2%<sup>16</sup>”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=In%20the%20extension%20study%2C%20at,22.7%25%3B%20Aubagio%20to%20KESIMPTA%20switch%2C)

> “Limitations: This analysis represents chance findings. The open-label extension study is not blinded, not controlled, and includes inherit self-selection bias for remaining in the trial. This study is an ongoing trial and the data presented are an interim analysis. No conclusions of statistical or clinical significance can be drawn.”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=Limitations%3A%20This%20analysis%20represents%20chance%20findings.%20The%20open%2Dlabel%20extension%20study%20is%20not%20blinded%2C%20not%20controlled%2C%20and%20includes%20inherit%20self%2Dselection%20bias%20for%20remaining%20in%20the%20trial.%20This%20study%20is%20an%20ongoing%20trial%20and%20the%20data%20presented%20are%20an%20interim%20analysis.%20No%20conclusions%20of%20statistical%20or%20clinical%20significance%20can%20be%20drawn.,-Treatment%2Dna%C3%AFve%20CDP%20Data)

> “ALITHIOS study design: ALITHIOS is an open-label, umbrella extension, Phase 3b, single-arm study evaluating long-term (up to 7 years) data. The primary objective was to assess safety and tolerability (N=1969) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) (including drop outs) from the ASCLEPIOS I/II, APLIOS, and APOLITOS trials. APLIOS (N=284) was a phase 2,12-week, open-label, parallel-group study. APOLITOS (N=62) is a phase 2, 24-week, double blind, placebo-controlled, parallel-group core-part followed by an open-label extension-part for up to 48 weeks, study in Japan and Russia. The secondary objective was to assess efficacy (N=1367) in patients with RMS who had at least 1 dose of KESIMPTA (20mg SC) from the ASCLEPIOS I and II trials who continued or switched to KESIMPTA treatment. A long-term (up to 7 years) analysis (n=465) was conducted to evaluate efficacy in the recently diagnosed treatment-naïve subgroup treated with KESIMPTA.<sup>4-9</sup>”

Source: [KESIMPTA: Clinical Trial Results, captured 2026-11-13](https://www.kesimptahcp.com/efficacy/clinical-trial-results#:~:text=ALITHIOS%20study%20design%3A%20ALITHIOS%20is,diagnosed%20treatment%2Dna%C3%AFve%20subgroup%20treated%20with)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
